Ascites and hepatorenal syndrome: pathophysiology and management
- PMID: 8790265
- DOI: 10.4065/71.9.874
Ascites and hepatorenal syndrome: pathophysiology and management
Abstract
Ascites, a late manifestation of cirrhosis of the liver, causes increased morbidity and mortality. The renin-angiotensin-aldosterone system, the sympathetic nervous system, and arginine vasopressin are responsible for sodium and water retention in patients with cirrhosis. Fluid localizes to the peritoneal cavity mainly as a result of portal hypertension. Recent developments in the understanding of the pathophysiologic mechanisms of ascites include the role of inadequate renal prostaglandin production in the development of the hepatorenal syndrome and the possible role of nitric oxide in the pathogenesis of the renal complications of cirrhosis. The aim of medical therapy is to achieve a negative sodium balance and, consequently, fluid loss. Large-volume paracentesis is safe and effective in the management of tense ascites, but use of diuretic agents should be continued to prevent reaccumulation of ascites. Liver transplantation, transjugular intrahepatic portosystemic shunts, or LeVeen shunts should be considered in selected patients with persistent ascites. In patients with diuretic-resistant or diuretic-refractory ascites, a thorough assessment must be performed to exclude potentially reversible causes. The hepatorenal syndrome has an associated grave prognosis, especially in patients who are not candidates for liver transplantation.
Comment in
-
Serum-ascitic fluid albumin gradient, portal hypertension, and ascites.Mayo Clin Proc. 1997 May;72(5):487. doi: 10.1016/S0025-6196(11)64872-6. Mayo Clin Proc. 1997. PMID: 9146695 No abstract available.
Similar articles
-
Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.Ann Ital Med Int. 1999 Oct-Dec;14(4):264-84. Ann Ital Med Int. 1999. PMID: 10638019 Review.
-
Ascites and Hepatorenal Syndrome.Clin Liver Dis. 2019 Nov;23(4):659-682. doi: 10.1016/j.cld.2019.06.002. Epub 2019 Aug 7. Clin Liver Dis. 2019. PMID: 31563217 Review.
-
Pathophysiology and treatment of ascites and the hepatorenal syndrome.Baillieres Clin Gastroenterol. 1992 Sep;6(3):581-607. doi: 10.1016/0950-3528(92)90040-l. Baillieres Clin Gastroenterol. 1992. PMID: 1421601 Review.
-
Management of ascites and hepatorenal syndrome.Hepatol Int. 2018 Feb;12(Suppl 1):122-134. doi: 10.1007/s12072-017-9815-0. Epub 2017 Aug 23. Hepatol Int. 2018. PMID: 28836115 Review.
-
Fluid retention in cirrhosis: pathophysiology and management.QJM. 2008 Feb;101(2):71-85. doi: 10.1093/qjmed/hcm121. Epub 2008 Jan 9. QJM. 2008. PMID: 18184668 Review.
Cited by
-
Management of cardiopulmonary complications of cirrhosis.Int J Hepatol. 2011;2011:280569. doi: 10.4061/2011/280569. Epub 2011 Jul 19. Int J Hepatol. 2011. PMID: 21994850 Free PMC article.
-
Sodium-Glucose Cotransporter-2 Inhibitors in Liver Cirrhosis: A Systematic Review of Their Role in Ascites Management, Slowing Disease Progression, and Safety.Int J Mol Sci. 2025 May 16;26(10):4781. doi: 10.3390/ijms26104781. Int J Mol Sci. 2025. PMID: 40429923 Free PMC article. Review.
-
Hepatorenal syndrome: an update.Sao Paulo Med J. 2007 Jan 4;125(1):50-6. doi: 10.1590/s1516-31802007000100010. Sao Paulo Med J. 2007. PMID: 17505686 Free PMC article. Review.
-
Perioperative management of liver surgery-review on pathophysiology of liver disease and liver failure.Eur Surg. 2018;50(3):81-86. doi: 10.1007/s10353-018-0522-4. Epub 2018 Apr 13. Eur Surg. 2018. PMID: 29875796 Free PMC article.
-
The Covert Side of Ascites in Cirrhosis: Cellular and Molecular Aspects.Biomedicines. 2025 Mar 10;13(3):680. doi: 10.3390/biomedicines13030680. Biomedicines. 2025. PMID: 40149656 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources